KRAS and non-small cell lung carcinoma: A recent significant advancement in molecular-targeted therapy is the approval of sotorasib for second-line treatment in NSCLC cases with Kirsten rat sarcoma viral oncogene homolog (KRAS) G12C mutation, following immunotherapy-based therapies (54).